Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer

10 Jan 2022

Abstract excerpt

Although radiation therapy has recently made great advances in cancer treatment, the majority of patients diagnosed with pancreatic cancer (PC) cannot achieve satisfactory outcomes due to intrinsic and acquired radioresistance. Identifying the molecular mechanisms that impair the efficacy of radiotherapy and targeting these pathways are essential to improve the radiation response of PC patients. Our goal is to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35053488
DOI: 10.3390/cancers14020326

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic CancerPMID 35053488Read ↗

Simultaneous CRISPR-Cas9-induced double strand breaks are lethal in models of pancreatic cancerSemantic proximity Read ↗

Inhibition of Non-Homologous End Joining Repair Impairs Pancreatic Cancer Growth and Enhances Radiation ResponseSemantic proximity Read ↗

Defective homologous recombination and genomic instability predict increased responsiveness to carbon ion radiotherapy in pancreatic cancerSemantic proximity Read ↗

DDB2 expression lights the way for precision radiotherapy response in PDAC cells, with or without olaparibSemantic proximity Read ↗

CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.Semantic proximity Read ↗

A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant overexpression of cyclin D1 and p21Semantic proximity Read ↗

Targeting DNA Damage Response and Replication Stress in Pancreatic CancerSemantic proximity Read ↗

Unbiased analysis of pancreatic cancer radiation resistance reveals cholesterol biosynthesis as a novel target for radiosensitisationSemantic proximity Read ↗

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancerSemantic proximity Read ↗

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cellsSemantic proximity Read ↗

Targeting DNA Damage Response and Replication Stress in Pancreatic CancerSemantic proximity Read ↗

A genome-wide screen reveals that Dyrk1A kinase promotes nucleotide excision repair by preventing aberrant co-stabilization of cyclin D1 and p21Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.